Related references
Note: Only part of the references are listed.Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
Qin-fang Deng et al.
JOURNAL OF CANCER (2020)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor
Uma Devi Bommu et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2018)
Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation
Run-Ze Li et al.
CELL DEATH & DISEASE (2018)
Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells
Miao Wang et al.
Oncotarget (2018)
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Nele Van Der Steen et al.
CANCER DRUG RESISTANCE (2018)
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
Stefanie Keller et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
Bing Wang et al.
ONCOLOGY LETTERS (2017)
EGFR G796D mutation mediates resistance to osimertinib
Di Zheng et al.
ONCOTARGET (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC
Katerina Ancevski Hunter et al.
Journal of Thoracic Oncology (2017)
BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology
Michael K. Gilson et al.
NUCLEIC ACIDS RESEARCH (2016)
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation
Petra Minder et al.
NEOPLASIA (2015)
3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer
Yuqiao Sheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors
Sugunadevi Sakkiah et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2014)
Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Suresh Kumar et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
Mingli Xiang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Genomics and Bioinformatics of Parkinson's Disease
Sonja W. Scholz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines
H. Li et al.
ADVANCES IN MEDICAL SCIENCES (2011)
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Kenji Takeuchi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Takeshi Yoshida et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
The epidermal growth factor receptor family: Biology driving targeted therapeutics
M. J. Wieduwilt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Validation studies of the site-directed docking program LibDock
Shashidhar N. Rao et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line
Atsuko Ogino et al.
CANCER RESEARCH (2007)
Receptor tyrosine kinases: mechanisms of activation and signaling
Stevan R. Hubbard et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
Lanxi Song et al.
CANCER RESEARCH (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma
P Sunpaweravong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization
KM Ferguson et al.
MOLECULAR CELL (2003)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
AJ Barker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Share Paper
